Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation

NCT07536724 is registered in ClinicalTrials.gov with Medira GmbH as lead sponsor.

NCT NCT07536724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07536724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation
Lead sponsor
Medira GmbH
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
November 30, 2027
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic tricuspid regurgitation (tr) graded as severe or greater